LAG3 and ovarian cancer: In the ovarian cancer model, the results suggested that the inhibition of the PD-1 or LAG-3 pathways alone was insufficient to control ovarian cancer, whereas the combined blockade with anti-LAG-3 and anti-PD-1 antibodies significantly delayed the growth of IE9mp1 ovarian tumors (P ═ 0.01) [65].